Raj Chovatiya, MD, PhD

Experts in the management of atopic dermatitis assess the use of JAK inhibitors in clinical practice and considerations for treatment selection for patients with atopic dermatitis.

Elizabeth A. Swanson, MD, describes the burden of atopic dermatitis on the pediatric and adult patient populations.

Raj J. Chovatiya, MD, PhD, reviews the clinical manifestations and underdiagnoses of atopic dermatitis.

Alexandra K. Golant, MD; Raj J. Chovatiya, MD, PhD; and Eric Simpson, MD, MCR, share their approach to prescribing decisions for oral and topical JAK inhibitors for patients with atopic dermatitis.

Drs Alexandra K. Golant, Raj J. Chovatiya, Linda Stein Gold, and Eric Simpson comment on clinical implications of boxed warnings for the utilization of JAK inhibitors when treating atopic dermatitis.

Korey Capozza, MPH, offers insight into changing public perception of atopic dermatitis and bridging unmet needs in the field.

Taylor and Tina Capps assess the burden of atopic dermatitis on Taylor’s life and the impact on her family.

Eric Simpson, MD, MCR, leads a discussion on current FDA approved topical and systemic JAK inhibitors for the management of atopic dermatitis.

Alexandra K. Golant, MD, highlights factors to consider when recommending the use of JAK inhibitors to manage atopic dermatitis for various patient populations.

Taylor and Tina Capps comment on Taylor’s experience of treatment regimens early on and the impact of underlying medical conditions on her atopic dermatitis.

Taylor Capps and her mother, Tina Capps, share Taylor’s initial journey with atopic dermatitis and presenting symptoms.

Raj J. Chovatiya, MD, PhD, provides an overview of JAK inhibitors and their use in atopic dermatitis treatment.

Alexandra K. Golant, MD; Raj. Chovatiya, MD, PhD; and Eric Simpson, MD, MCR, discuss goals of therapy for patients with atopic dermatitis and challenges physicians face in management of the disease.

Eric Simpson, MD, MCR, reviews conventional topical and systemic therapy treatment options for the management of atopic dermatitis.

Drs Eric Simpson, Alexandra K. Golant, and Raj J. Chovatiya share their approaches to atopic dermatitis care.

Raj J. Chovatiya, MD, PhD, comments on the impact of atopic dermatitis on the quality of life for patients and their families.

Eric Simpson, MD, MCR; and Alexandra K. Golant, MD, provide an overview of the pathophysiology of atopic dermatitis and detail how to approach an atopic dermatitis diagnosis.

Closing out its discussion on atopic dermatitis, the panel considers best practices and unmet needs in the treatment landscape.

A brief discussion on when it is best to switch therapy while treating patients for atopic dermatitis.

Shared insight on the armamentarium of systemic agents available to treat atopic dermatitis.

A review of topical therapies that have been long utilized for patients with atopic dermatitis.

A brief review of patient and disease factors that inform selection of therapy for atopic dermatitis.

Expert insight on nonpharmacological strategies to treat atopic dermatitis and improve patient quality of life.

A brief evaluation of the concomitant use of JAK inhibitors, topical or systemic, in patients with atopic dermatitis.

Switching its focus to systemic JAK inhibitors, the panel reviews real-world use of available agents to treat patients with atopic dermatitis.

The panelists discuss real-world use of topical ruxolitinib in atopic dermatitis management given safety, efficacy, and availability.

Considerations for topical ruxolitinib with deference to positive clinical trial results in atopic dermatitis.

Shared insight on the available JAK inhibitors for atopic dermatitis, both topical and systemic.

Experts reflect on the various comorbid conditions associated with atopic dermatitis and how they can affect patients.

Comprehensive discussion on how atopic dermatitis can impact a patient’s quality of life.